Advate Alternatives Compared
| Advate (antihemophilic factor) | Hemlibra (emicizumab) | Recombinate (antihemophilic factor) |
|
|---|
| Advate (antihemophilic factor) | Hemlibra (emicizumab) | Recombinate (antihemophilic factor) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hemophilia A. Advate may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A, Hemophilia A with Inhibitors. Hemlibra may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A. Recombinate may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||||||||||
| More about Advate (antihemophilic factor) | More about Hemlibra (emicizumab) | More about Recombinate (antihemophilic factor) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Advate has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Hemlibra has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Recombinate has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Advate side effects |
View all Hemlibra side effects |
View all Recombinate side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Advate prices |
View all Hemlibra prices |
View all Recombinate prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other antihemophilic factor brands include: Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Recombinate, Xyntha View more |
N/A |
Other antihemophilic factor brands include: Advate, Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Xyntha View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
24 hours |
667.2 hours |
24 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 10 drugs are known to interact with Advate:
|
A total of 8 drugs are known to interact with Hemlibra:
|
A total of 10 drugs are known to interact with Recombinate:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
November 16, 2017 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Lysteda
Lysteda (tranexamic acid) is used to treat heavy menstrual bleeding. Includes Lysteda side effects ...
DDAVP
DDAVP is used for diabetes insipidus, hemophilia a, primary nocturnal enuresis, von Willebrand Disease
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Qfitlia
Qfitlia is used for hemophilia a, hemophilia a with inhibitors, hemophilia b, hemophilia b with ...
Altuviiio
Altuviiio is a once-weekly recombinant fact VIII replacement therapy used by hemophilia A patients ...
Cyklokapron
Cyklokapron is used for bleeding disorder, factor ix deficiency, hemophilia a
Hemlibra
Hemlibra is a monoclonal antibody that functions in place of a natural blood-clotting factor that ...
Hympavzi
Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.